Anthem Biosciences cash flow

Latest FY26
Cash from operations
₹844cr 
Capital spending
₹211cr 
Free cash flow
₹633cr 
Cash from financing
−₹40.0cr 
₹ crore except per share
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026
Adjustments to reconcile profit — non-cash items
—134
—2.4
—−14.4
—35.1
Changes in working capital
—216
—−126
—65.1
—−7.1
—−34.9
—−9.5
—−1.9
—40.0
—−2.1
Cash from operating activities
783824
—297
—1,121
—−79.3
—−6.9
—204
—844
Cash from investing activities
—211
—3.8
—1.6
—79.3
—−575
—−702
Cash from financing activities
—26.6
—57.9
—1.8
—6.9
—0.0
—−40.0
—103
—−0.3
—103
Reference items
793834
39.6%39.3%
633633
₹11.27₹11.27
73.63×—
—1.43×
—204
—6.9
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ANTHEM₹830.15

Anthem Biosciences Ltd.

· Pharma & Health
₹ CrorePeersSYNGENEDIVISLABGLAXOAJANTPHARMIPCALABABBOTINDIAMEDANTAGLENMARKMcap ₹46,631 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation134.1—
+ Fair Value (Gains) / Losses2.4—
+ Unrealised FX (Gain) / Loss-14.4—
+ Other Non-cash Items35.1—
Changes in Working Capital
+ Inventories215.9—
+ Trade Receivables — Current-126.1—
+ Other Current Assets65.1—
+ Other Non-current Assets-7.1—
+ Trade Payables — Current-34.9—
+ Other Financial Liabilities — Current-9.5—
+ Other Financial Liabilities — Non-current-1.9—
+ Other Current Liabilities40.0—
+ Provisions — Current-2.1—
Cash from Operating Activities
Profit Before Tax (per I/S)824.2782.6
+ Total Adjustments (incl. Working Capital)296.6—
Cash from Operations (pre-tax)1,120.9—
+ Interest Received — Operating-79.3—
+ Interest Paid — Operating-6.9—
+ Income Taxes Paid204.0—
Cash from Operating Activities844.5—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)211.2—
+ Disp of Fixed Assets3.8—
+ Sale of Investments (Equity / Debt)1.6—
+ Interest Received — Investing79.3—
+ Other Inflows / (Outflows) — Investing-575.0—
Cash from Investing Activities-701.6—
Cash from Financing Activities
+ Proceeds from Issue of Shares26.6—
+ Repayment of Borrowings57.9—
+ Payment of Lease Liabilities1.8—
+ Interest Paid6.9—
+ Other Inflows / (Outflows) — Financing0.0—
Cash from Financing Activities-40.0—
Net Changes in Cash (pre-FX)102.9—
+ Effect of FX Rate Changes on Cash-0.3—
Net Changes in Cash102.6—
Reference Items
EBITDA833.8792.9
EBITDA Margin %39.2539.60
Free Cash Flow (CFO − Capex)633.3633.3
Free Cash Flow per Basic Share11.2711.27
Price to Free Cash Flow—73.63
Cash Flow to Net Income1.43—
Cash Paid for Taxes204.0—
Cash Paid for Interest6.9—
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.